Spruce Biosciences launches site for planned TA-ERT Sanfilippo B confirmatory trial in Q4 2026
SPRB•Planned study details
The Expanded Access Program targets children with attenuated or severe Sanfilippo type B who cannot join the confirmatory study; about 10 participants.
TrAnsform is a randomized controlled study in severe disease, comparing investigational therapy versus standard care; about 14 participants.
The programs aim to evaluate safety and whether treatment can preserve cognitive function, supporting a planned FDA review pathway.
Site launched for planned Sanfilippo B programs
Spruce Biosciences launched MPS3BStudy.com to register interest for planned U.S. access and trial programs for tralesinidase alfa.
No study results were presented; both the Expanded Access Program and TrAnsform confirmatory study are slated to start as early as Q4 2026.
